EYPT JPM Presentation January 2025 vF (2).pdf

《EYPT JPM Presentation January 2025 vF (2).pdf》由會員分享，可在線閱讀，更多相關《EYPT JPM Presentation January 2025 vF (2).pdf（30頁珍藏版）》請在三個皮匠報告上搜索。

1、J.P.Morgan Healthcare Conference PresentationJanuary 14,2025Jay Duker,M.D.President and CEO2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.Legal Disclaimers2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.2Various statements made in this presentation are forward-looking,within the meaning

2、 of the U.S.Private Securities Litigation Reform Act of 1995,and are inherently subject to risks,uncertainties and potentially inaccurate assumptions.All statements that address activities,events or developments that we intend,expect,plan or believe may occur in the future,are forward-looking statem

3、ents,including but not limited to statements regarding:our expectations regarding the timing and clinical development of DURAVYU in Wet AMD and DME,our expectations regarding the enrollment,dosing and data readouts for the LUGANO trial and the LUCIA trial;our optimism that that DURAVYU has the poten

4、tial to change the current treatment paradigm and revolutionize real-world outcomes for patients suffering from serious retinal diseases;our belief that DURAVYU has the potential to maintain a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer;an

5、d our expectations regarding the timing and clinical development of our other product candidates,including EYP-2301.Forward-looking statements by their nature address matters that are,to different degrees,uncertain.Uncertainties and risks may cause EyePoints actual results to be materially different

6、 than those expressed in or implied by EyePoints forward-looking statements.For EyePoint,these risks and uncertainties include the timing,progress and results of the companys clinical development activities;uncertainties and delays relating to the design,enrollment,completion,and results of clinical

7、 trials;unanticipated costs and expenses;the companys cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated;the risk that results of clinical trials may not be predictive of future results,and interim and preliminary data are subject to further anal

8、ysis and may change as more data becomes available;unexpected safety or efficacy data observed during clinical trials;uncertainties related to the regulatory authorization or approval process,and available development and regulatory pathways for approval of the companys product candidates;changes in

9、 the regulatory environment;changes in expected or existing competition;the success of current and future license agreements;our dependence on contract research organizations,and other outside vendors and service providers;product liability;the impact of general business and economic conditions;prot

10、ection of our intellectual property and avoiding intellectual property infringement;retention of key personnel;delays,interruptions or failures in the manufacture and supply of our product candidates;the availability of and the need for additional financing;our ability to obtain additional funding t

11、o support our clinical development programs;uncertainties regarding the timing and results of the August 2022 subpoena from the U.S.Attorneys Office for the District of Massachusetts;uncertainties regarding the FDA warning letter pertaining to our Watertown,MA manufacturing facility;and other factor

12、s described in our filings with the Securities and Exchange Commission(SEC).More detailed information on these and additional factors that could affect our actual results are described in our filings with the SEC,including our Annual Report on Form 10-K for the fiscal year ended December 31,2023,as

13、revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC.We cannot guarantee that the results and other expectations expressed,anticipated or implied in any forward-looking statement will be realized.A variety of factors,including these risks,could cause o

14、ur actual results and other expectations to differ materially from the anticipated results or other expectations expressed,anticipated or implied in our forward-looking statements.Should known or unknown risks materialize,or should underlying assumptions prove inaccurate,actual results could differ

15、materially from past results and those anticipated,estimated or projected in the forward-looking statements.You should bear this in mind as you consider any forward-looking statements.Our forward-looking statements speak only as of the dates on which they are made.EyePoint undertakes no obligation t

16、o update or revise any forward-looking statement,whether as a result of new information,future events,or otherwise.The Leader in Sustained Release Drug Delivery for Retinal Disease2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.Most robust dataset in wet AMD among all sustained delivery progra

17、msMost robust dataset in wet AMD among all sustained delivery programsTwo ongoing global Phase 3 non-inferiority pivotal trials in wet AMDTwo ongoing global Phase 3 non-inferiority pivotal trials in wet AMDStrong balance sheet with$370M in cash and equivalents1;cash runway into 2027Strong balance sh

18、eet with$370M in cash and equivalents1;cash runway into 2027DURAVYU:patent protected vorolanib featuring new MOA delivered via best-in-class technology,Durasert EDURAVYU:patent protected vorolanib featuring new MOA delivered via best-in-class technology,Durasert EOnly sustained release TKI with acti

19、ve program in DME bolstered by highly positive interim Phase 2 clinical dataOnly sustained release TKI with active program in DME bolstered by highly positive interim Phase 2 clinical data1.As of December 31,2024.Unaudited estimate,inclusive of net proceeds from October 2024 equity financing.MOA,mec

20、hanism of action;wet AMD,wet age-related macular degeneration;DME,diabetic macular edema1234532025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.4wet AMD,wet age-related macular degeneration;DME,diabetic macular edema;PK,pharmacokinetic;GA,geographic atrophyPipeline Leveraging Durasert EDrug Deli

21、very Technologytrial underwaynon-clinicalAnticipated Next MilestonePhase 3Phase 2Phase 1Pre-ClinDiscoveryIndicationDurasert EProgramsWet AMDDURAVYU(vorolanib intravitreal insert)(f/k/a EYP-1901)DMEserious retinal diseasesEYP-2301 razuprotafib(TIE-2 agonist)Enrollment completion in 2H 2025Full data Q

22、1 2025FDA meeting expected Q2 2025Pre-clin tox and PK dataPIVOTAL TRIALS UNDERWAY POSITIVE INTERIM BCVA AND CST DATAEvaluating additional pipeline opportunities5IVT,intravitrealDURASERT ETECHNOLOGYSustained-Release Drug Delivery Standard in-office IVT injection Continuous dosing Zero-order kinetics

23、drug releaseBioerodible Durasert E:Solid injectable insert Drug formulated within a bioerodible matrix Designed to release drug load before matrix fully erodes Favorable safety profile across multiple indications2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.Insert is 1/5000 of Vitreous Volum

24、eInsert is 1/5000 of Vitreous Volume 2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.61.Bakri SJ,et al.PLoS One.2024;19(6):e0304782 CC BY 4.0.TKI tyrosine kinase inhibitor;AMD,age-related macular degeneration;Ang,angiopoietin;FGF(R),fibroblast growth factor(receptor);PDGF(R),platelet-derived g

25、rowth factor(receptor);PLGF,placental growth factor;TKI,tyrosine kinase inhibitor;TIE2,tyrosine-protein kinase receptor TIE-2;VEGF(R),vascular endothelial growth factor(receptor);VE-PTP,vascular endothelial cell-specific protein tyrosine phosphatase.Vorolanib is a Best-In-Class TKI that Selectively

26、Inhibits all Forms of the VEGF ReceptorPotent and highly selective pan-VEGF receptor inhibitorComposition of matter patent into 2037Acts intracellularly to preventpro-angiogenic signalingDemonstrated neuroprotectionPotential antifibroticDoes not inhibit TIE21Potent and highly selective pan-VEGF rece

27、ptor inhibitorComposition of matter patent into 2037Acts intracellularly to preventpro-angiogenic signalingDemonstrated neuroprotectionPotential antifibroticDoes not inhibit TIE21Endothelial cellVEGFBVEGFAVEGFCVEGFDVEGFR1VEGFR2VEGFR3TIE2PDGFRANG1ANG2PDGFAngiogenesis,permeability,leakage,growth,migra

28、tion,and proliferationBlood vessel stabilityProliferation,motilityPLGFPericyteVOROLANIBVOROLANIBPathological angiogenesis and vascular instability underlie wet AMD2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.7Immediately bioavailable reaches therapeutic levels within hoursConstant dosing ze

29、ro-order kineticsrelease for at least six months Controlled drug release bioerodible matrix controls drug release;no free-floating drugContains NO PEG or PLGAPreloaded sterile syringe injectorShipped and stored at ambient temperatureDURAVYU:Vorolanib in Bioerodible Durasert EBioerodible Insert 94%dr

30、ug 1/5000 of vitreous volume2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.8DURAVYU Demonstrated Positive Efficacy and Favorable Safety Profile Across Multiple Clinical Trials and Indications1.Interim data as of October 1,2024.Preliminary data which may differ from future results of the same

31、trial,or different conclusions or considerations may qualify such results,once additional data have been received fully evaluated.Wet AMD,wet age-related macular degeneration;NPDR,non-proliferative diabetic retinopathy;DME,diabetic macular edema;SAEs,serious adverse events;BCVA,best-correct visual a

32、cuity;OCT,optical coherence tomography.Key Efficacy OutcomesSafetyIndicationClinical Trial Stable BCVA and CST 74%reduction in treatment burdenNODURAVYU RELATEDOCULAR ORSYSTEMICSAESwet AMDDAVIO Statistically non-inferior BCVA vs on-label aflibercept 80%reduction in treatment burden Stable anatomy(CS

33、T)wet AMDDAVIO 2 Stable or prevention of worsening disease severityNPDRPAVIA Improvement in BCVA and CST vs.aflibercept control at 16 weeksDMEVERONA1DURAVYU HASBEENEVALUATED INOVER190 PATIENTS TODATEACROSSMULTIPLEINDICATIONS2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.Phase 2 DAVIO 2 Positi

34、ve Results inwet AMD as a 6-Month Maintenance TherapyA NON-INFERIORITY TRIAL VERSUS AN AFLIBERCEPT CONTROLDAVIO 2 is Randomized,Double-Masked,Aflibercept Controlled*Clinical Trial to Assess Efficacy and Safety of DURAVYU at Two Doses2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.10*Aflibercep

35、t on-label control required by FDA-D14 to-D7D1W4W8W12W16W24W32W36 to W56W20W28DURAVYU 2mg low dosen=53DURAVYU 3mg high dosen=54Aflibercept2mg q8Wn=54RANDOMIZATIONREQUIRED AFLIBERCEPT INJECTION VISITVISIT SCHEDULEDDURAVYU DOSEAFLIBERCEPT q8WOn-labelDURAVYU or SHAM AFTER3RDAFLIBERCEPT LOADING DOSE1 EN

36、DPOINT BLEND W28 AND W32;UNMASK W32SHAM INJECTION FOR MASKINGSUPPLEMENTAL ANTI-VEGF INJECTION BASED ON PRE-SPECIFIED CRITERIA2024 EyePoint Pharmaceuticals,Inc.All Rights Reserved.11DURAVYU Phase 2 DAVIO 2 Clinical Trial Met All Endpoints3mg dose2mg doseDAVIO 2 Endpoint-0.4 letters-0.3 lettersPrimary

37、:Non-inferior change in BCVA vs.aflibercept No DURAVYU-related SAEs Secondary:Favorable safety profile185%89%Secondary:Reduction in treatment burden vs.6 mos.prior76%82%Secondary:Reduction in treatment burden vs.aflibercept63%83%of eyes had 0 or 1 supplemental injections63%88%of eyes had 0 or 1 supp

38、lemental injections Secondary:Supplement-free up to 6 months+5.2um+12.4um Secondary:Anatomical control vs.aflibercept+1.0*+1.3*+0.9*-0.5-0.1-0.52025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.12DURAVYU was Statistically Non-Inferior in Change in BCVA Compared to the Aflibercept Control*Blended

39、 week 28 and week 32 change vs.baseline*Month 8 represents 6 months after DURAVYU injection1 AAO 2022 presentation,Paolo Lanzetta,on behalf of the PULSAR study investigatorsMEAN CHANGE IN BCVA FROM BASELINEIn the Pulsar trial,HD Eylea(16-week 8mg arm)change in BCVA vs.2mg Eylea was-1.4 letters1-15-1

40、0-5051015Randomization Month 1Month 2(DURAVYU insert)Month 3Month 4Month 5Month 6Month 7Month 8*Change in ETRDS lettersAfliberceptMonth 9Month 10Month 11Month 12AfliberceptAfliberceptAfliberceptAfliberceptMean Change in BCVA vs Aflibercept at Six MonthsDURAVYU 2mg-0.3*DURAVYU 3mg-0.4*Primary Endpoin

41、t:+10.6 um+17.8 um+5.4 um+11.2 um+21.2 um+11.1 um2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.13DURAVYU Treated Patients Showed Strong Anatomic Control*Month 8 represents 6 months after DURAVYU injectionMEAN CHANGE IN CST-100-75-50-250255075100Randomization Month 1Month 2(DURAVYU insert)Mon

42、th 3Month 4Month 5Month 6Month 7Month 8*CST Change,in micronsAfliberceptMonth 9Month 10Month 11Month 12AfliberceptAfliberceptAfliberceptAfliberceptMean Change in CST vs Aflibercept at Six MonthsDURAVYU 2mg+12.4DURAVYU 3mg+5.2Meaningful Supplement-Free Rates in Eyes Treated with DURAVYU Support DURAV

43、YU as a Potential 6-Month Treatment for Wet AMD2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.14*First visit patients are eligible to be supplemented*Month 8 represents 6 months post DURAVYU injectionSUMMARY OF SUPPLEMENT-FREE RATES BY MONTH100%100%98%75%63%79%63%98%0%20%40%60%80%100%Afliberc

44、eptAfliberceptAflibercept96%Month 9Month 10Month 11Month 1257%47%55%52%87%86%Month 2(DURAVYU insert)Month 3*Month 4Month 5Month 6Month 7Month 8*AfliberceptAflibercept100%100%94%2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.DURAVYULUGANO/LUCIAPhase 3 Pivotal Trials in wet AMDNON-INFERIORITY V

45、ERSUS AN AFLIBERCEPT CONTROLPhase 3 Trials are Designed to Enable Global Regulatory Approvals for DURAVYU 2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.16Demonstrate DURAVYU,when administered every six months,achieves similar visual outcomes to on-label aflibercept while reducing treatment b

46、urden400 endpoint for NDA submission400 patients per trialTwo arms2.7mg DURAVYU aflibercept on-label controlDURAVYU dosing every 6-monthsOne-year efficacy and safety endpoint for NDA submissionPrimary Endpoint:difference in mean change in BCVA from Day 1 to Week 52 and 56(blended)versus aflibercept

47、controlSecondary endpoints:safety,reduction in treatment burden,percent of eyes supplement-free,anatomical stabilityLUGANO ANDLUCIA TRIALS:GLOBAL,RANDOMIZED,DOUBLE-MASKED,AFLIBERCEPTCONTROLLEDOBJECTIVETRIALDESIGNENDPOINTSDURAVYUin Wet AMD Phase 3 Pivotal Trial Design2025 EyePoint Pharmaceuticals,Inc

48、.All Rights Reserved.17ScreeningD1W4W8W12 W16W24W32W84-W92W20W28DURAVYU2.7mgAflibercept2mg q8WRANDOMIZATIONREQUIRED AFLIBERCEPT INJECTION VISITVISIT SCHEDULEDDURAVYUDOSEAFLIBERCEPT q8W1 ENDPOINT BLEND W52 AND W56;UNMASK W56SHAM INJECTION FOR MASKINGW36 W40 W44 W48 W52 W56W60-W76W80W96 EOSAFLIBERCEPT

49、 Q8WSHAM INJECTION FOR MASKING SUPPLEMENTAL ANTI-VEGF INJECTION BASED ON STRICT CRITERIAAFLIBERCEPTLOADDURAVYUDURAVYUDURAVYUDURAVYUExceptional Enrollment to Date Driven by Significant Investigator and Patient Enthusiasm2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.18June 2024Final Phase 3 pr

50、otocolsOctober 2024First patient in LUGANO trial dosedDecember 2024First patient in LUCIA trial dosed2H2025Expected full enrollment of both Phase 3 pivotal trialsTop line data for both Phase 3 pivotal trials anticipated in 2026January 2025LUGANO trial 1/3 enrolled;LUCIA exceeding expectations2026Top

51、line data for pivotal program2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.Phase 2 VERONA Clinical Trial in DME 16-Week Interim ResultsALL PATIENTS HAVE COMPLETED THE WEEK 16 VISITDME,diabetic macular edemaInterim data as of October 1,2024.Preliminary data which may differ from future result

52、s of the same trial,or different conclusions or considerations may qualify such results,once additional data have been received and fully evaluated.2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.20DME,diabetic macular edema;VEGF,vascular endothelial growth factor;BCVA,best corrected visual ac

53、uity;OCT,optical coherence tomography;CST,central subfield thicknessDURAVYU DOSINGVISIT SCHEDULEDAFLIBERCEPT INJECTIONSHAM INJECTIONDURAVYU1.3mg(n=10)DURAVYU2.7mg(n=11)Aflibercept2mg single injection(n=6)SUPPLEMENTAL ANTI-VEGF INJECTION BASED ON PRESPECIFIED CRITERIAObjectives:Evaluate the safety an

54、d efficacy of DURAVYU in DME Collect dose-ranging data to inform Phase 3 clinical trialsPrimary endpoint:time to supplemental anti-VEGF injection up to week 24Key Secondary endpoints:safety,change in BCVA vs.aflibercept control and anatomical control(CST)PRIMARY ENDPOINT-D28 to-D7D1W4W8W12W16W20W24P

55、hase 2 VERONA Clinical Trial is a Randomized,Open-Label,Aflibercept Controlled Trial as a Potential Treatment for DMEVERONA:Baseline BCVA and CST Demonstrate Patients with Active DME(CST 325m)2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.21DURAVYU 2.7mg(n=11)DURAVYU 1.3mg(n=10)Aflibercept 2m

56、g(n=6)65.5(46-75)66.9(53-75)67.5(57-73)Mean BCVA,ETDRS letters(range)421.0(329-557)405.2(342-589)400.3(341-463)Mean CST,m(range)BCVA,best-corrected visual acuity;CST,central subfield thickness;DME,diabetic macular edema;ETDRS,Early treatment diabetic retinopathy studyInterim data as of October 1,202

57、4.Preliminary data which may differ from future results of the same trial,or different conclusions or considerations may qualify such results,once additional data have been received and fully evaluated.051015RandomizationWeek 4Week 8Week 12Week 16Change in ETRDS lettersaflibercept 2mg(n=6)DURAVYU 1.

58、3mg(n=10)DURAVYU 2.7mg(n=11)2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.22VERONA:DURAVYU 2.7mg Demonstrated Clinically Meaningful Improvement in BCVA at 16 Weeks Six Letters Better vs.Aflibercept ControlDURAVYU 2.7mg+5.7Mean Change in BCVA vs AfliberceptDURAVYU 1.3mg+0.6+3.8+8.9+3.2MEAN CH

59、ANGE IN BCVA FROM BASELINEBCVA,best-corrected visual acuityInterim data as of October 1,2024.Preliminary data which may differ from future results of the same trial,or different conclusions or considerations may qualify such results,once additional data have been received and fully evaluated.2025 Ey

60、ePoint Pharmaceuticals,Inc.All Rights Reserved.23VERONA:Improved and Controlled Anatomy Demonstrated with DURAVYU 2.7mg and Mirror BCVA Results 38 Microns Improved vs.Aflibercept ControlMean Change in CST vs AfliberceptDURAVYU 1.3mg-8.5 um-39.0 um-68.1 um-30.5 umMEAN CHANGE IN CST FROM BASELINECST:c

61、entral subfield thicknessInterim data as of October 1,2024.Preliminary data which may differ from future results of the same trial,or different conclusions or considerations may qualify such results,once additional data have been received and fully evaluated.-85-75-65-55-45-35-25-15-5515Randomizatio

62、nWeek 4Week 8Week 12Week 16CST Change,in micronsaflibercept 2mg(n=6)DURAVYU 1.3mg(n=10)DURAVYU 2.7mg(n=11)DURAVYU 2.7mg-37.6 umVERONA:Eyes Treated with DURAVYU had a Greater Proportion of Supplement-Free Eyes vs.Aflibercept Control at 16 Weeks2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.24S

63、UMMARY OF CUMULATIVE SUPPLEMENT-FREE RATES BY WEEK*100%100%82%82%100%90%60%100%100%83%50%0%20%40%60%80%100%Week 4Week 8Week 12Week 16DURAVYU 2.7mg(n=11)DURAVYU 1.3mg(n=10)aflibercept control(n=6)100%*Time to aflibercept supplementation and supplement rates will be analyzed once all patients have com

64、pleted the trial.Interim data as of October 1,2024.Preliminary data which may differ from future results of the same trial,or different conclusions or considerations may qualify such results,once additional data have been received and fully evaluated.Majority of the rescue(80%)were given due to the

65、lack of 10%reduction in CST from baselineVERONA:Positive Interim Data Supports DURAVYU as a Potential Treatment for DMEData support potential for vision improvement in DME as well as superior dosing intervals2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.25DURAVYU 2.7MG EFFICACY 16-WEEK RESUL

66、TS:Early and sustained BCVA improvementEarly and sustained CST improvementGreater proportion of supplement-free eyes vs.aflibercept control1Improvements in BCVA and CST appear to be driven by treatment with DURAVYU and not supplemental injectionsDURAVYU OVERALL SAFETY RESULTS:No ocular or systemic D

67、URAVYU-related SAEsNo cases of:EndophthalmitisRetinal vasculitis(occlusive or non-occlusive)Intraocular inflammation(IOI)Insert migration into the anterior chamber1.Time to aflibercept supplementation and supplement rates will be analyzed once all patients have completed the trial.DME,diabetic macul

68、ar edema;BCVA,best-corrected visual acuity;CST,central subfield thickness;SAEs,serious adverse events.Interim data as of October 1,2024.Preliminary data which may differ from future results of the same trial,or different conclusions or considerations may qualify such results,once additional data hav

69、e been received and fully evaluated.Commercial Manufacturing Facility Opened in October 20242025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.26FDA,Federal Drug Administration;EMA,European Medicines Agency;cGMP,current good manufacturing practiceLocated in Northbridge,MABuilt to US FDA and EU EM

70、A standards40,000sf cGMP manufacturing facility Built to EYPT specifications by landlord preserving upfront cash investmentNew manufacturing site for commercial production of DURAVYU2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.EYP-2301:razuprotafib in Durasert EA SUSTAINED DELIVERY TIE-2 AG

71、ONIST FOR SEVERE RETINAL DISEASESEYP-2301:Razuprotafib in Durasert Eis a Patented TIE-2 Agonist as a Potential New MOA for Treating Serious Retinal Diseases2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.281.Heier et al.Retina,2021;41:1-19.and Joussen et al.Eye 2021;35:1305-1316.;2.Hammes,et.A

72、l Diabetes.2011 Jan 1;3.Shen et al.JCI,2014;124:4564;3.Campochiaro et al.Ophthalmology,2016;123:1722-1730;4.Phase 2 TIME 2a clinical trial conducted by Aerpio.5.Campochiaro et al.PubMed 2016 123(8):1722-1730.DOI:10.1016/j.ophtha.2016.04.025EYP-2301 targets vascular endothelial protein tyrosine phosp

73、hatase(VE-PTP)activating TIE-2 and downregulating ANG2 to maintain vascular stability in the retinaPPEYP-2301Blood vessel lumen Intracellular spaceVE-PTPANG2Tie-2 activation combined with VEGF inhibition has the potential to enhance efficacy and extend durability1of treatmentRazuprotafib(f/k/a AKB-9

74、778)delivered subcutaneously demonstrated preclinical and clinical proof of concept in posterior segment disease2,3In a Phase 2 clinical trial,razuprotafibcombined with ranibizumab,was more effective than ranibizumab alone at reducing macular edema with a favorable safety and tolerability profile4,5

75、The Leader in Sustained Release Drug Delivery for Retinal Disease2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.Most robust dataset in wet AMD among all sustained delivery programsMost robust dataset in wet AMD among all sustained delivery programsTwo ongoing global Phase 3 non-inferiority pi

76、votal trials in wet AMDTwo ongoing global Phase 3 non-inferiority pivotal trials in wet AMDStrong balance sheet with$370M in cash and equivalents1;cash runway into 2027Strong balance sheet with$370M in cash and equivalents1;cash runway into 2027DURAVYU:patent protected vorolanib with new MOA deliver

77、ed via best-in-class technology,Durasert EDURAVYU:patent protected vorolanib with new MOA delivered via best-in-class technology,Durasert EOnly sustained release TKI with active program in DME bolstered by highly positive interim Phase 2 clinical dataOnly sustained release TKI with active program in

78、 DME bolstered by highly positive interim Phase 2 clinical data1.As of December 31,2024.Unaudited estimate,inclusive of net proceeds from October 2024 equity financing.MOA,mechanism of action;wet AMD,wet age-related macular degeneration;DME,diabetic macular edema1234529J.P.Morgan Healthcare Conference PresentationJanuary 14,2025Jay Duker,M.D.President and CEO2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.